Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas

Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques...

Full description

Bibliographic Details
Main Authors: Pejčić Ivica, Vrbić Svetislav, Todorović Mirjana, Petković Ivan, Balić Mirjana, Stanković Ana
Format: Article
Language:English
Published: Sciendo 2014-06-01
Series:Acta Facultatis Medicae Naissensis
Subjects:
CUP
Online Access:http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INT
id doaj-4bfb41010f0e4e25a01cf9e8d24fc48d
record_format Article
spelling doaj-4bfb41010f0e4e25a01cf9e8d24fc48d2020-11-25T01:05:22ZengSciendoActa Facultatis Medicae Naissensis2217-25212014-06-01312879410.2478/afmnai-2014-0010afmnai-2014-0010Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical DillemasPejčić Ivica0Vrbić Svetislav1Todorović Mirjana2Petković Ivan3Balić Mirjana4Stanković Ana5Clinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaClinic of Oncology, Clinical Centre Niš, SerbiaMetastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in efficacy (efficiency) of indentifying the primary site of disseminated disease. That is why a diagnostic procedure should be rational and should include the basic diagnostic examination (analyses) with the aim to define biological and clinical characteristics of diagnosed disease, as well as an optimal therapeutic approach. Although the overall prognosis of the majority of these patients is poor, it is possible, nowadays, to distinguish the subgroups of patients with favorable prognosis. Results of new basic research, better understanding of pathogenesis at the molecular level and introduction of new drugs through clinical trials suggest an advance in this disease treatment and outcome.http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INTmalignant tumormetastaseschemotherapyCUP
collection DOAJ
language English
format Article
sources DOAJ
author Pejčić Ivica
Vrbić Svetislav
Todorović Mirjana
Petković Ivan
Balić Mirjana
Stanković Ana
spellingShingle Pejčić Ivica
Vrbić Svetislav
Todorović Mirjana
Petković Ivan
Balić Mirjana
Stanković Ana
Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
Acta Facultatis Medicae Naissensis
malignant tumor
metastases
chemotherapy
CUP
author_facet Pejčić Ivica
Vrbić Svetislav
Todorović Mirjana
Petković Ivan
Balić Mirjana
Stanković Ana
author_sort Pejčić Ivica
title Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
title_short Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
title_full Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
title_fullStr Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
title_full_unstemmed Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas
title_sort cancer of unknown primary site syndrome‐cup syndrome - diagnostic and therapeutical dillemas
publisher Sciendo
series Acta Facultatis Medicae Naissensis
issn 2217-2521
publishDate 2014-06-01
description Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in efficacy (efficiency) of indentifying the primary site of disseminated disease. That is why a diagnostic procedure should be rational and should include the basic diagnostic examination (analyses) with the aim to define biological and clinical characteristics of diagnosed disease, as well as an optimal therapeutic approach. Although the overall prognosis of the majority of these patients is poor, it is possible, nowadays, to distinguish the subgroups of patients with favorable prognosis. Results of new basic research, better understanding of pathogenesis at the molecular level and introduction of new drugs through clinical trials suggest an advance in this disease treatment and outcome.
topic malignant tumor
metastases
chemotherapy
CUP
url http://www.degruyter.com/view/j/afmnai.2014.31.issue-2/afmnai-2014-0010/afmnai-2014-0010.xml?format=INT
work_keys_str_mv AT pejcicivica cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
AT vrbicsvetislav cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
AT todorovicmirjana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
AT petkovicivan cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
AT balicmirjana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
AT stankovicana cancerofunknownprimarysitesyndromecupsyndromediagnosticandtherapeuticaldillemas
_version_ 1725194891611340800